Semnur Pharmaceuticals, Inc. (SMNR)
| Market Cap | 1.15B +869.5% |
| Revenue (ttm) | n/a |
| Net Income | -164.33M |
| EPS | -0.77 |
| Shares Out | 230.21M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 500 |
| Open | 5.00 |
| Previous Close | 4.95 |
| Day's Range | 5.00 - 5.00 |
| 52-Week Range | 3.00 - 23.00 |
| Beta | 0.14 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 12, 2026 |
About Semnur Pharmaceuticals
Semnur Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its lead product candidate is SP-102, a novel viscous gel formulation of corticosteroid to treat lumbosacral radicular pain, or sciatica, which is in the second Phase 3 study. The company was founded in 2013 and is headquartered in Palo Alto, California. Semnur Pharmaceuticals, Inc. operates as a subsidiary of Scilex Holding Company. [Read more]
Financial Performance
Financial StatementsNews
Scilex approves dividend of Semnur Pharmaceuticals shares
Scilex (SCLX) announced that its board of directors approved a dividend of Semnur Pharmaceuticals (SMNR) common stock held by the company to its stockholders and certain other eligible equityholders o...